Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thioesterase superfamily member 4 (THEM4), also known as CTMP (carboxyl-terminal modulator protein), encodes an enzyme with acyl-CoA thioesterase activity that hydrolyzes medium- and long-chain fatty acyl-CoA thioesters (C14–C18), suggesting a role in mitochondrial fatty acid metabolism. THEM4 is best known for its regulatory function as a negative modulator of protein kinase B (AKT1/PKB) by inhibiting its phosphorylation at the C-terminal, thereby impacting signal transduction pathways involved in cell survival and apoptosis. The expression of THEM4 is commonly reduced in various cancers, including glioblastomas, and it has been implicated in apoptotic signaling and disease progression[1][2][4][6].
Modulation of PKB/AKT1 phosphorylation status (for molecules that could target this protein)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thioesterase superfamily member 4 (THEM4).